← Leaderboards
Noah A Craft
Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center
$2,798,027
Attributed
$2,798,027
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2008–12$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$2,798,027 · 7
By mechanism
R01$1,786,585 · 1
K22$485,190 · 1
R21$454,200 · 1
M01$72,052 · 4
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Imiquimod”
- Mary P Stenzel-Poore · Oregon Health And Science University$9,698,022
- Swey-Shen Chen · Institute Of Genetics$4,054,921
- David E Fisher · Massachusetts General Hospital$3,378,474
- Patrick M Gaffney · University Of Minnesota Twin Cities$3,262,348
- Kit S Lam · University Of California At Davis$3,035,824
- Cornelia L Trimble · Johns Hopkins University$3,027,180
Research focus
ImiquimodImmune ResponseFutureGrantResearch PersonnelBaseInfectionPathogenListeria MonocytogenesPathway InteractionsAgonistLifeMelanomaMouse ModelIn VitroImmunoregulationRecombinantsImmuneImmune SystemImmunityCombinatorialAffectLeadResearch Design
Grant awards (16)
Immunomodulation in melanoma therapy$275,908
R01 · FY2012 · CA · contact PI
Immunomodulation in melanoma therapy$275,908
R01 · FY2011 · CA · contact PI
Immunomodulation in melanoma therapy$291,164
R01 · FY2010 · CA · contact PI
Immunomodulation in melanoma: Toll like receptors and therapeutic vaccines$161,730
K22 · FY2010 · CA · contact PI
IMMUNOMODULATION BY IMIQUIMOD IN PRIMARY MELANOMA$4,608
M01 · FY2010 · RR · contact PI
Immunomodulation in melanoma therapy$368,000
R01 · FY2009 · CA · contact PI
Immunomodulation in melanoma therapy$291,164
R01 · FY2009 · CA · contact PI
Killed But Metabolically Active Leishmania: a novel protozoan vaccine technology$204,600
R21 · FY2009 · AI · contact PI
Immunomodulation in melanoma: Toll like receptors and therapeutic vaccines$161,730
K22 · FY2009 · CA · contact PI
Killed But Metabolically Active Leishmania: a novel protozoan vaccine technology$60,000
R21 · FY2009 · AI · contact PI
IMPROVING DIAGNOSTIC ACCURACY AND DEFINING THE EPIDEMIOLOGY OF CELLULITIS$53,982
M01 · FY2009 · RR · contact PI
IMMUNOMODULATION BY IMIQUIMOD IN PRIMARY MELANOMA$13,031
M01 · FY2009 · RR · contact PI
IMMUNOMODULATION BY IMIQUIMOD IN PRIMARY MELANOMA$431
M01 · FY2009 · RR · contact PI
Immunomodulation in melanoma therapy$284,441
R01 · FY2008 · CA · contact PI
Killed But Metabolically Active Leishmania: a novel protozoan vaccine technology$189,600
R21 · FY2008 · AI · contact PI
Immunomodulation in melanoma: Toll like receptors and therapeutic vaccines$161,730
K22 · FY2008 · CA · contact PI